-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Health
Latest From Health
New study shows hepatitis C burden may ease in future
Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis C will shrink in the coming decades thanks to new medicines and increased screening regimens. Currently, approximately one in 100 people are infected with the virus, and researchers expect that number to drop to about one in 1,500 people by 2036 if patients have timely and affordable treatment. “We were pleasantly surprised that in the next 22 years we could Read More >
NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”
Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >
Treating Hepatitis C: Too Costly Not to Act
Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act – by California Healthcare Institute’s Todd Gillenwater on the value of breakthrough Hepatitis C medicines that cure the disease in the majority of patients. As Gillenwater asserts, “New hepatitis C drugs mark a paradigm shift – from a model of somewhat iffy but costly chronic care to a model of short-term curative treatment with equal or slightly lower costs paid Read More >
New Report: Innovation in Hepatitis C Treatment
Today, the California Healthcare Institute released a report on the public health impact of Hepatitis C and the potential of groundbreaking new treatments to save tens of thousands of lives over the coming decades. Innovation in Hepatitis C Treatment: New Opportunities for Action explores the incredible progress that has been made in Hepatitis C treatment in the decades since the Hepatitis C virus was identified as the cause of the disease in 1989. Early treatments Read More >
BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight
BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >
